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Abstract
Purpose: Disturbed axonal transport is an important pathogenic factor in many neurodegenerative diseases, such as
glaucoma, an eye disease characterised by progressive atrophy of the optic nerve. Quantification of retrograde axonal
transport in the optic nerve usually requires labour intensive histochemical techniques or expensive equipment for in vivo
imaging. Here, we report on a robust alternative method using Fluorogold (FG) as tracer, which is spectrometrically
quantified in retinal tissue lysate.
Methods: To determine parameters reflecting the relative FG content of a sample FG was dissolved in retinal lysates at
different concentrations and spectra were obtained. For validation in vivo FG was injected uni- or bilaterally into the
superior colliculus (SC) of Sprague Dawley rats. The retinal lysate was analysed after 3, 5 and 7 days to determine the time
course of FG accumulation in the retina (n=15). In subsequent experiments axona transport was impaired by optic nerve
crush (n=3), laser-induced ocular hypertension (n=5) or colchicine treatment to the SC (n=10).
Results: Spectrometry at 370 nm excitation revealed two emission peaks at 430 and 610 nm. We devised a formula to
calculate the relative FG content (cFG), from the emission spectrum. cFG is proportional to the real FG concentration as it
corrects for variations of retinal protein concentration in the lysate. After SC injection, cFG monotonously increases with time
(p=0.002). Optic nerve axonal damage caused a significant decrease of cFG (crush p=0.029; hypertension p=0.025;
colchicine p=0.006). Lysates are amenable to subsequent protein analysis.
Conclusions: Spectrometrical FG detection in retinal lysates allows for quantitative assessment of retrograde axonal
transport using standard laboratory equipment. It is faster than histochemical techniques and may also complement
morphological in vivo analyses.
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Introduction
A characteristic element of neurons is their axon, which, as in
retinal ganglion cells (RGCs), can be several orders of magnitude
longer than the cell body. To maintain cellular functions in the
remote areas of the axon a transport system is required which
carries various cargoes, such as proteins and membrane-encapsu-
lated vesicles from the soma to the axon ending (anterogradely) or
in the opposite direction (retrogradely).[1–3] Axonal transport is
different from diffusion as the cargo is actively moved by motor
protein ATPases which run along a ‘track’ formed by microtubuli
or actin. [4].
In the eye, impairment of retrograde axonal transport is
considered an important pathogenic factor in glaucoma [5–9], a
degenerative disease of retinal ganglion cells (RGCs) which is the
second leading cause of irreversible blindness in the world. [10]
Besides glaucoma, optic nerve trauma is also characterised by an
early breakdown of the axonal transport system. [11].
To assess axonal transport in vivo, tracer substances are
introduced into a distinct neuronal area either at the soma or at
the axon ending. The amount of tracer that subsequently
accumulates at the other end of the neuron is taken as a measure
of transport capacity. The detection of the tracer for quantification
is most commonly done post mortem on tissue sections using either
radioactivity (e.g. I
125-BDNF) [5], enzymatic activity (mainly
horseradish-peroxidase) [12–14] or fluorescence. [15] A main
limitation of this approach is that significant amounts of tracer
may get lost during tissue processing. Furthermore, careful
sectioning and densitometric analysis are relatively labour
intensive and background noise often largely varies between
histological sections.
To allow a more direct measurement of axonal transport
different approaches for in vivo detection of tracers have recently
been described. They comprise in vivo retinal imaging of
fluorescent tracers (Choe TE et al. IOVS 2011;52: ARVO E-
Abstract 2448), magnetic resonance imaging with manganese
chloride as tracer [11,16,17] or direct observation of fluorescently
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require considerable investments and highly skilled personnel,
which limits their widespread implementation.
Here, we report on a robust and technically less demanding
method to quantify the retrograde axonal transport capacity in the
rat optic nerve by using Fluorogold (FG) as tracer substance, which
is spectrometrically detected in retinal lysate. FG is known to be
taken up by the cell through endocytosis, presumably pinocytosis,
There is no passive diffusion through the cell membrane. Packed
in endocytotic vesicles it is actively transported in both directions,
ante- and retrogradely. [18] FG has been used for decades as the
standard dye for retrograde labelling of RGCs. [15] It shows little
fading, is non-toxic in standard concentrations and does not leak
from axons while transported. [18].
The method consists of three experimental steps:
1. Injection of FG into the superior colliculus.
2. Sacrificing of the animal at a specific timepoint, explantation of
the retina and lysis of the retinal tissue following standard
protocols for western blotting.
3. Spectrometric analysis of the retinal lysate in a fluorescence
microplate reader. The resulting emission data provide a direct
measure (cFG) for the amount of FG that has accumulated in
the retina.
Following the spectrometric measurement, the samples can be
further used for specific protein analysis e.g. by western blotting.
Methods
Ethics Statement
All animals used in this study were treated in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. The protocols were approved by the Commis-
sion on the Use of Animals in Scientific Procedures of the local
government (Tierversuchskommission, Regierungspra ¨sidium Frei-
burg, Germany; permit number: G-10/106).
Animals
A total of 33 Sprague Dawley rats, weight 275 to 400 g were
used for all in vivo and in vitro experiments. The specifications of
the rats used for the in vivo experiments were as follows: Time
course of FG accumulation in normal retinae: 13 female rats,
weight 300–350 g; optic nerve crush: 3 male rats, weight 275–
300 g, ocular hypertension: 5 male rats, weight 275–300 g,
colchicine injection: 10 male rats, weight 275–300 g.
Optic nerve crush
Optic nerve crush was performed as previously described. [19]
Briefly, rats were anaesthetised with isofluorane. The orbit was
opened through an incision at the superior orbital rim and the
optic nerve was approached by partially resecting the lacrimal
gland. The optic nerve sheath was cut open longitudinally 1–
2 mm posterior to the globe, while care was taken not to damage
blood vessels. The optic nerve was crushed with blunt forceps for
10 s. Before wound closure the retinal perfusion was checked
funduscopically. Animals with severe reduction of the perfusion
were excluded.
Laser-induced Ocular Hypertension Model
Laser treatment to the trabecular meshwork to rise intraocular
pressure (IOP) was performed as previously described. [20] Briefly,
after intraperitoneal anaesthesia with Ketamine/Xylazine 60 to 70
laser spots from a frequency doubled 532 nm argon laser were
directed to whole circumference of the aqueous outflow tract
located underneath the periphery of the cornea. Laser setting were
100 mm diameter spot size, 500 mW power and 500 ms duration.
IOP was measured before and at day 1 and 5 after treatment
using a TonoLab device (Thiolat, Finland).
Superior Colliculus Injection of Fluorogold and Colchicine
Animals were deeply anaesthetised with isoflurane. Crystalline
Fluorogold (Fluoro-Gold, Fluorochrome, Denver, USA) was
resolved as 3% solution in PBS containing 10% DMSO. The
skull was exposed and three holes were drilled above the superior
colliculus 1 mm lateral to the sagittal and the lambdoidal suture
with the central hole being placed at the level of the suture
intersection and the other two holes lying 1 mm anterior and
posterior to it. A total volume of 3.6 ml FG solution (1.2 ml per
hole) was injected using a Hamilton syringe (Hamilton, Bonaduz,
Switzerland) mounted on a stereotactic frame (Stoelting, Kiel,
Germany). The volume injected into each hole was divided into
two equal parts injected at two different levels, 4.2 mm and
4.7 mm below the pia mater. After each injection the needle was
left in place for 1 min to avoid reflux of the solution.
For disruption of the microtubular network colchicine (or an
equal volume of pure PBS for control injections; Sigma-Aldrich,
Munich, Germany) was added to the FG solution. The total
injection volume for all three holes was 3.9 ml. The solution
contained the same amount of FG as for all other injections plus
0.66 ml of a 30 mg/ml colchicine in PBS solution (or 0.66 ml PBS
for control injections).
Processing of the Retina
Animals were killed with increasing concentration of CO2 and
the eye was excised from the orbit. To explant the retina, the eye
was cut open circularly behind the ciliary body to separate cornea
and lens from the posterior portion of the eyeball. The retina was
carefully detached from the pigment epithelium and fully
separated from the sclera by transection of the proximal optic
nerve. The retinal tissue was disrupted with an ultrasound probe
(Sonopuls, Bandelin; Berlin, Germany) in 150 ml of standard lysis
buffer used for western blotting (RIPA buffer containing standard
amounts of protease and phosphatase inhibitors (Complete mini,
Roche, Germany; plus 200 mM sodium orthovanadate)). The
lysate was kept on ice and used immediately for spectrometry.
Spectrometry of Retinal Lysate
For spectrometry the samples, each consisting of 140 ml retinal
lysate, were transferred to a black 96 well plate (Greiner Cellstar;
Frickenhausen, Germany). All measurements were carried out on
an Infinite M200 device (Tecan, Crailsheim, Germany). The
excitation wavelength was set to 370 nm. Emission was measured
between 400 and 700 nm in 10 nm increments. The gain was set
constant throughout all measurements.
Results
We have developed a spectrometric approach to reliably
quantify FG in retinal tissue lysates and validated the technique
in several in vitro experiments. Subsequently, the spectrometric
axonal transport measurement was applied to animals with a
healthy optic nerve and to animals with experimentally impaired
axonal transport for comparison.
Spectrometric Quantification of FG in Retinal Lysate
The spectrum of Fluorogold in retinal lysate exhibits two
peaks at 430 and 610 nm. Before studying FG emission, the
Axonal Transport Quantification with Fluorogold
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determined using a 1:5000 solution of FG in RIPA lysis buffer.
Within a range of 300 to 700 nm excitation wavelength (emission
detection at 630 nm) a wavelength of 370 nm showed the highest
emission (data not shown) and was therefore used throughout all
following experiments.
The emission spectrum of pure FG in RIPA lysis buffer exhibits
two peaks at 440 and 610 nm (Fig. 1A, dashed line). Pure retinal
lysate in standard western blot concentration shows a peak of
autofluorescence at 425 nm, which slowly decreases with higher
wavelengths (Fig. 1A, black line). Testing RIPA lysis buffer alone
revealed very low emission between 400 and 500 nm and no
significant emission above 500 nm. (Fig. 1A, grey line).
When adding increasing amounts of FG to retinal lysate
(Fig. 1B), two peaks emerge at 430 and 610 nm with a trough at
520 nm. (Fig. 1B, white dotted lines) While the peak at 430 nm is a
composite result of retinal autofluorescence and FG signal, the
second peak at 610 nm is mainly determined by the FG content
alone.
The relative FG concentration cFG in a sample can be
calculated from the peak/trough (610/520 nm)
emission. In order to determine the spectrometric parameter
that best reflects the FG content in a retinal sample, we conducted
in vitro experiments with varying concentrations of retinal protein
and FG. When selecting the appropriate parameter from the
spectrometric curve, one has to take into account that during
excision of the retina from the eyeball, some retinal tissue
containing FG is lost, which may vary in different preparations.
Consequently, in the analysed sample (which has always a constant
volume of sample buffer) the mixture of retinal protein and FG
would be more or less diluted. However, given that FG positive
RGCs are evenly distributed in the peripheral retina (as
demonstrated in supplemental appendix S1 and figure S1) the
ratio of FG to retinal protein would always remain constant. For
this reason the ideal spectrometric parameter for quantification of
the FG content in the retina should reflect the FG/retinal protein
ratio rather than the absolute amount of FG in the analysed
sample. The 610 nm FG peak emission, however, correlates with
the absolute amount of FG and would, therefore, be directly
influenced by variations of retinal volume.
The spectrometric curves of retinal lysate with different
concentrations of FG in Fig. 1B show that with rising FG/retinal
protein ratio the slope of the curve between the 520 nm trough
and the 610 nm peak gradually increases. We hypothesised that
variations in the dissected retinal volume would result in an up- or
downshift of the emission curve by a certain dilution factor.
Hence, normalising the emission curves would eliminate the
dilution factor and the slope of the normalised curves should
reflect the FG/retinal protein ratio. To test this hypothesis we
simulated variations in retinal volume by dilution of retinal lysate
containing FG with RIPA lysis buffer and compared the resulting
raw and normalised emission spectra. To normalise the spectrum
between 520 (trough) and 610 nm (second peak) all emission
values (E520 to 610) were divided by the emission value at 520 nm
(E520). (Fig. 2 A,B).
The raw spectra indicate decreased signal intensities with
increasing sample dilution (Fig. 2A). Normalisation of these
emission spectra revealed that the slope of the emission curve
(E520 to 610) was independent of the sample dilution (Fig. 2B). In
contrast, variations of the FG/retinal tissue ratio (Fig. 2C) resulted
in different slopes of the normalised emission curve (Fig. 2D).
Thus, the curve endpoint (encircled in Fig. 2D), used as a
surrogate for the slope, reflects the FG/retinal protein ratio.
To quantify the difference in FG content between experimental
samples the fact that the normalised emission (en) for lysate
containing no FG (en
0) is not zero has to be taken into account (see
Fig. 2D). The en of a sample containing FG (en
x) adds to this
baseline value. Thus, to calculate the relative FG content (cFG)o fa
sample the en
x value needs to be normalised to en
0. This results in:
cFG~
ex
n{e0
n
e0
n
with ex
n~
Ex
610
Ex
520
normalised emission of an FG containing sample x ðÞ ,
e0
n~
E0
610
E0
520
(normalised emission of pure lysate without FG) and
Figure 1. Spectrometry of FG and retinal lysate. A) Spectra of pure FG (interrupted line; 1: 5000 dilution) and retinal lysate (black line). The
diluent for both was RIPA lysis buffer (grey line). B) Spectra of retinal lysate containing different amounts of FG (white dotted lines). Pure retinal lysate
without FG (black dots) and RIPA lysis buffer (grey dots) are shown for comparison. With increasing FG concentration the slope of the curve between
520 and 610 nm increases.
doi:10.1371/journal.pone.0038820.g001
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Consequently, besides the groups of experimental and control
retinae which provide the en
x data a small group of normal retinae
without FG from the same strain, sex and age of rats is necessary
in order to obtain the background en
0 values. In our experiments
the group size of these normal retina samples was n=3 and 4. The
mean of the en
0 values was used to calculate the cFG of each
experimental sample. Once en
0 is determined it can be used for all
samples as long as animal strain, sex and age remain unchanged.
Supplemental data (see appendix S2 and figure S2) further
characterise the quantitative relation of cFG and the real FG
content.
Spectrometric Analysis of FG Retrograde Axonal
Transport in the Rat Optic Nerve
Time course of FG accumulation in the normal
retina. We determined the time course of FG accumulation in
the retina by FG injection into the right superior colliculus and
measurement of the spectrometric signal in the retinal lysate of the
contralateral eye after three, five and seven days. Fig. 3 shows the
gradual increase of the normalised curve slope and the cFG value
with time. The difference between the control eye group and all
three timepoints was statistically significant (p,0.0002; one-way
Figure 2. Raw and normalised spectra of retinal lysate from untreated animals with FG added in vitro. A and B) Dilution series of
retinal lysate containing a constant proportion of FG. 100% is the undiluted sample. 80% and 50% is the content of lysate in the diluted samples. The
dilution was done with RIPA lysis buffer. A) Raw emission spectra. The dotted vertical lines mark the 520 to 610 nm range that was normalised in B.
B) Spectra after normalisation to the E520 value. The curves of the undiluted and the diluted samples are now congruent, indicating that the
normalisation compensates for the effect of different sample dilutions. C and D) Retinal lysate with increasing concentrations of FG. C) Raw emission
spectra. The dotted vertical lines mark the 520 to 610 nm range that was normalised in D. D) Spectra after normalisation to the E520 value. The end
points of the normalised curves are encircled. They increase with higher FG concentration.
doi:10.1371/journal.pone.0038820.g002
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the control eyes, the difference between the control eyes and day
five and seven was significant (day three: p.0.05; day five:
p,0.01; day seven: p,0.001; Bonferroni’s multiple comparison
test).
As the difference between control and day three was not
statistically different in the post hoc analysis we chose day five as
the timepoint appearing most appropriate to detect differences in
FG transport in the following in vivo experiments.
Spectrometric quantification of axonal transport
impairment. To assess whether the method is capable of
detecting axonal transport impairment, we conducted three
independent in vivo experiments. Optic nerve damage was
induced by either: 1. optic nerve crush for an acute severe axonal
injury, 2. ocular hypertension for a more mild axonal damage or 3.
colchicine injection in the superior colliculus for pharmacological
disruption of the microtubuli network in the optic nerve axons.
For optic nerve crush (n=3) or laser treatment to induce ocular
hypertension (n=5) FG was injected into both superior colliculi
and the damaging treatment was performed unilaterally during the
same anaesthesia. In the laser treated eyes the intraocular pressure
at day one was 34.865.3 mmHg (mean and SEM) higher than in
the contralateral control eye. As known for this laser model, the
pressure had returned to almost normal level at day five
(1.263.3 mmHg above control).
For microtubular disruption, colchicine (or PBS for control) was
injected together with FG into the right superior colliculus (n=5
for treatment and control group). The spectrometric measure-
ments were done at the left eye as the contralateral eye is
predominantly affected in albino animals due to crossing of more
than 90% of the axons.
In all cases the cFG value was determined from retinal lysate five
days after treatment. The en
0 used for all calculations was obtained
by averaging the measurements of four retinae without FG
(en
0=0.32460.014). All three modes of damage showed signifi-
cantly less FG in the retinal lysates of treated eyes compared to
untreated control eyes (Fig. 4 A-F; cFG mean 6 SEM for untreated
and treated eye; one-tailed t-test: optic nerve crush: 1.8560.5 and
20.00560.004, p=0.029; ocular hypertension: 1.8060.19 and
1.5360.22, p=0.025; colchicine: 1.8060.06 and 1.3060.10,
p=0.006). In the optic nerve crush group cFG was reduced to
levels of FG-free controls (Fig. 4 A,B). In the ocular hypertension
model with a less severe optic nerve damage, a smaller reduction
in FG levels was detected. In the colchicine group, a moderate but
highly significant drop in axonal transport capacity was detected
(Fig. 4).
After spectrometric measurement the retinal lysate can be
further used for western blotting. The FG itself as well as the
spectrometry procedure do not seem to cause any interference
with the subsequent western blot (Fig. 4G). When probing for
phospho-Erk1/2 there was no indication for increased protein
degradation or dephosphorylation.
Discussion
We have developed a method to quantify the retrograde axonal
transport capacity in the rat optic nerve by fluorogold (FG)
superior colliculus injection and subsequent spectrometric detec-
tion of FG in retinal lysate. The relative FG concentration in the
tissue lysate, cFG, is calculated from the spectrometric emission
measured at 610 and 520 nm in the experimental sample and a
FG-free reference.
A significant increase of FG signal above baseline was detected
from day five after superior colliculus injection. Therefore, this
timepoint was chosen in transport interruption studies. Choosing
day seven might have resulted in a slightly stronger signal with
better differentiation of different grades of transport impairment.
However, we found choosing the earliest significant timepoint
more sensible because the timecourse of FG accumulation shows a
steep rise from day three to five and levels off after day five. This
suggests saturation of the neurons and increasing anterograde
transport of FG from the soma back to the axon ending at later
time points. Also, the FG concentration at the superior colliculus
slowly decreases with time as a consequence of diffusion into larger
brain areas and drainage to the blood vessels. Therefore, choosing
the most dynamic phase of FG accumulation in the retina provides
the highest chance to detect a transport impairment in neurode-
generation. For rapidly developing neurodegeneration, even the
five day observation time may be too long. But for more slowly
progressing disease models like chronic glaucoma or generalised
Figure 3. FG accumulation in the retina by retrograde transport over time. Normalised emission curves (A) and relative FG content in the
lysate (cFG; B) in control retinal lysate and at three different timepoints after FG injection. The data points and bars are the mean and SEM for each
group. The group size is given in panel A. The difference between control and days five and seven are statistically significant (p,0.01 and 0.001,
respectively).
doi:10.1371/journal.pone.0038820.g003
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release their FG during the observation period, the tracer would
still appear in the lysate and be available for detection.
By normalisation of the raw spectra our method compensates
for variations in the retinal volume retrieved (Fig. 2). This
eliminates the need for a separate method to acquire the sample
protein concentration. The normalised emission curve of diluted
samples was similar to undiluted samples up to a dilution of 50%
(Fig. 2 A,B). This would control for a much higher variability of
protein concentration than observed in typical experiments. In a
study measuring the weight of nine consecutive retinae dissected in
our laboratory we determined a variation coefficient of 11%.
A source of error when using the spectrometric method would
be the comparison of groups injected with different preparations of
FG working dilutions. Variations in pipetting as well as fading of
fluorescence over time may lead to erroneous results. Therefore,
each experimental group of animals needs an individual control
group injected with the same FG solution, preferably at the same
day.
The primary goal in developing the method was to measure
axonal transport as a functional parameter. It was not designed to
replace RGC counts for neurodegeneration or neuroprotection
studies. Although the number of RGCs and the amount of FG in
the retina somehow correlate, spectrometry does not distinguish
between FG in viable RGCs and FG released from dead RGCs.
However, by carefully choosing the timepoint of FG injection and
sampling, the spectrometric measurement may provide additional
valuable information about RGC survival. For example, in a
slowly progressing neurodegenerative disease FG injections at
different timepoints each followed by spectrometry five days later
would result in a value that is not only dependent on the number
of physically present RGCs (like RGC counts) but would also
reflect the RGC’s ability to carry out axonal transport. This
approach, however, requires careful validation which was beyond
the scope of the present work.
Besides the much shorter data acquisition time another
advantage of FG spectrometry over histological detection methods
is that the tissue lysates can be used for further analyses. The FG
present (molecular weight approx. 500 Daltons) does not interfere
with SDS-Gel electrophoresis and wet-blotting procedures as
demonstrated in Fig. 4G.
Given that axonal transport impairment is considered a key
pathogenic factor in a variety of neurodegenerative diseases such
as amyotrophic lateral sclerosis, [21] X-linked Charcot-Marie
Tooth neuropathy [22] and hereditary spastic paraplegias [23] FG
spectrometry could be applied to any nerve and any direction of
transport. In cases where cargo binding is affected, such as in
Parkinson’s and Alzheimer’s disease [24], different cargo vesicles
may be differentially affected. Thus, the degree of transport
impairment of FG carrying vesicles may be different from
pathogenically relevant vesicles, for example those carrying
neurotrophic factors. [25] In all other cases where the disease
primarily affects the movement of the motor proteins (dynein or
kinesin, e.g. Huntigton’s disease) or the tubular ‘railroad’
(microtubuli) we consider a similar impact on the different types
of endocytotic vesicles.
If both FG injection area and target area are located in the
brain they need to be anatomically well separated to avoid tracer
Figure 4. FG accumulation in the retina after different types of optic nerve injury. A-F) Normalised emission curves (A, C, E) and cFG (B, D,
F) five days after optic nerve injury. Data points and error bars are mean and SEM. A, B) Optic nerve crush, n=3, p=0.029. C, D) Laser induced ocular
hypertension, n=5, p=0.025. E, F) Colchicine injection to the superior colliculus, n=5 for treatment and control group, p=0.006). G) Western blot
for phospho-Erk1/2 from control retinal lysate after superior colliculus injection of PBS (lane ‘‘C’’) and from retinal lysate used for FG spectrometry
(lane ‘‘F’’). Both lanes show a similar band pattern indicating that despite the FG labelling and spectrometric measurements the retinal lysate can be
further used for western blots.
doi:10.1371/journal.pone.0038820.g004
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variations in tissue protein concentration is particularly helpful
when working with neuronal projections to the brain, as tissue
volumes dissected from a particular brain area often vary largely.
However, this does not exclude sampling error. If a significant
amount of the dissected tissue is outside the neuron projection
zone the cFG will be falsely low.
In contrast to optical in vivo imaging systems which are
increasingly used in eye research, FG spectrometry uses ex vivo
tissue (retinal lysate) which requires a higher number of animals
when investigating different timepoints. Information on spatial
differences in the retinal transport between individual RGCs or
areas of the retina are lost. However, using a highly sensitive,
wavelength-specific and well calibrated detection system, which by
its measurement principle excludes a large number of variables
occurring in optical imaging in vivo, the spectrometric method is
particularly suitable for quantification purposes. This is also
reflected by the very low inter-measurement variability of the in
vitro measurements shown in shown in supplemental figure S2.
Our data suggest, that FG spectrometry may serve as a valuable
addition to in vivo imaging. Furthermore, FG spectrometry
provides a robust and low-cost tool to study axonal transport in the
optic nerve as a stand-alone system if more elaborate and
expensive techniques are not available.
Supporting Information
Appendix S1 Assessment of RGC density changes in the
outer periphery of the retina.
(DOC)
Appendix S2 Calculation of the relative FG content.
(DOC)
Figure S1 Quantification of RGC density changes in the
outer periphery of the retina. A) Schematic of a flatmounted
retina and the counting frame (dashed line), which is divided into a
central and peripheral sub-frame. The size of the counting frame
was enlarged for better visibility. B) Box plot of the peripheral to
central subframe RGC density (p/c ratio) of 4 retinae. The dashed
line indicates a p/c ratio of 1 (no difference between central and
peripheral sub-frame). There is no statistically significant differ-
ence to the value 1 (p=0.56) indicating that RGC density does not
change as a function of eccentricity in the outer periphery. C)
Representative image of FG labelled RGCs. Image size equals
counting frame size. The horizontal white line indicates the
boundary of the sub-frames. Top peripheral part, bottom central
part.
(TIF)
Figure S2 Relationship between relative and absolute
FG content. cFG plotted against rFG of retinal lysate with known
amounts of FG added. The data points are the mean and SEM of
n=3 samples. The interrupted line is the linear regression of the
data points. The plot demonstrates that the experimentally
determined cFG value is proportional to the real FG concentration
rFG.
(TIF)
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